SUPERNUS PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Supernus Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2011 to Q3 2024.
  • Supernus Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $38.5M.
  • Supernus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $60.7M, a 13.6% increase from 2021.
  • Supernus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $53.4M, a 57.9% decline from 2020.
  • Supernus Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was $127M, a 12.3% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $38.5M +$54.5M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $19.9M +$20.7M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-04
Q1 2024 $124K -$16.8M -99.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-04
Q3 2023 $25.6M -$16M -$17.7M -1013% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 $43.3M -$831K -$8.7M -111% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-04
Q1 2023 $52M $16.9M -$8.67M -33.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-04
Q4 2022 $60.7M $25.5M +$23M +943% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-09
Q3 2022 $37.7M $1.75M -$19.8M -91.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $57.5M $7.87M -$15.9M -66.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 $73.3M $25.6M +$19.9M +350% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 $53.4M $2.44M -$28.3M -92.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $81.8M $21.6M -$18.4M -46.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $100M $23.7M -$10.9M -31.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 $111M $5.69M -$15.8M -73.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 $127M $30.8M -$2.36M -7.13% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 $129M $40M +$11.1M +38.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $118M $34.7M +$1.94M +5.93% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-05
Q1 2020 $116M $21.5M +$3.18M +17.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-05
Q4 2019 $113M $33.1M +$7.24M +27.9% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-28
Q3 2019 $106M $28.9M +$849K +3.03% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $105M $32.7M +$1.99M +6.47% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-06
Q1 2019 $103M $18.3M -$8.01M -30.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-06
Q4 2018 $111M $25.9M +$12.2M +89.6% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 $98.8M $28M +$12.1M +75.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-28
Q2 2018 $86.7M $30.7M +$13.4M +77% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-28
Q1 2018 $73.3M $26.4M +$16.1M +156% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-28
Q4 2017 $57.3M $13.7M -$662K -4.62% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 $57.9M $16M -$45.9M -74.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 $104M $17.4M +$7.12M +69.4% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 $96.7M $10.3M +$5.47M +113% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 $91.2M $14.3M +$7.47M +109% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 $83.8M $61.8M +$57.9M +1479% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 $25.8M $10.3M +$7.81M +321% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 $18M $4.83M +$4.09M +554% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 $13.9M $6.85M +$3.07M +81% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 $10.9M $3.92M +$6.29M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 $4.59M $2.44M -$765K -23.9% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 $5.36M $738K +$16.3M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$10.9M $3.79M +$26.2M Oct 1, 2014 Dec 31, 2014 10-K/A 2017-01-20
Q3 2014 -$37.1M -$2.37M +$21.7M +90.2% Jul 1, 2014 Sep 30, 2014 10-K/A 2017-01-20
Q2 2014 -$58.8M $3.2M +$30.6M Apr 1, 2014 Jun 30, 2014 10-K/A 2017-01-20
Q1 2014 -$89.4M -$15.5M +$2.87M +15.6% Jan 1, 2014 Mar 31, 2014 10-K/A 2017-01-20
Q4 2013 -$92.3M -$22.4M -$8.89M -65.8% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 -$83.4M -$24.1M -$10.6M -78.7% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 -$72.8M -$27.4M -$17.3M -173% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 -$55.4M -$18.4M -$9.14M -98.5% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
Q4 2012 -$46.3M -$13.5M -$95.5M -116% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-21
Q3 2012 $49.2M -$13.5M -$3.75M -38.5% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-21
Q2 2012 $53M -$10M -$2.64M -35.7% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-21
Q1 2012 $55.6M -$9.28M +$1.77M +16% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-21
Q4 2011 $53.8M $82M Oct 1, 2011 Dec 31, 2011 10-K 2013-03-15
Q3 2011 -$9.73M Jul 1, 2011 Sep 30, 2011 10-K 2013-03-15
Q2 2011 -$7.38M Apr 1, 2011 Jun 30, 2011 10-K 2013-03-15
Q1 2011 -$11M Jan 1, 2011 Mar 31, 2011 10-K 2013-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.